Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
about
Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of actionHIV-1 integrase inhibitor resistance and its clinical implicationsCurrent perspectives on HIV-1 antiretroviral drug resistanceNovel therapeutic strategies targeting HIV integraseDesign of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to ResistanceMolecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)Activities, Crystal Structures, and Molecular Dynamics of Dihydro-1 H -isoindole Derivatives, Inhibitors of HIV-1 IntegraseLong-term efficacy and safety of raltegravir in the management of HIV infection.Approved Antiviral Drugs over the Past 50 YearsDNA suspension arrays: silencing discrete artifacts for high-sensitivity applicationsStructure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97AResistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitorsDolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kineticsNon-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cellsTherapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical TrialsRetroviral DNA IntegrationA note on partial covariate-adjustment and design considerations in noninferiority trials when patient-level data are not available.Comparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit.The maraviroc expanded access program - safety and efficacy data from an open-label study.An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule.Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.Dolutegravir: clinical efficacy and role in HIV therapy.A dynamic model of HIV integrase inhibition and drug resistance.The HIV-1 integrase α4-helix involved in LTR-DNA recognition is also a highly antigenic peptide elementBiochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravirAntiretroviral therapy in the clinicVirological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine CohortEvolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Raltegravir: The evidence of its therapeutic value in HIV-1 infection.Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DCBoosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.Resistance to integrase inhibitors.Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
P2860
Q24316120-A821537E-4FEA-413C-9BA5-F5C9998CAC48Q24628743-22DB4740-8C0F-48DB-A832-0B103DC00869Q26852626-846699D4-60EC-4989-917D-90727E70F6F9Q27003960-47015754-E8B4-4F71-A00D-F300ED7D8AE5Q27664086-27E7A31D-379E-4E86-91A3-834DC1263125Q27665427-D5F0DE7E-66CA-4B29-9404-DE31281406F4Q27670616-E509B87E-2676-440C-B9FA-463042A2AE52Q27674615-95A5B531-3694-4C41-9404-B37070E5FA5CQ27686870-F9F1DF6E-47D8-45BD-B486-30C653716A35Q27755387-4A7A1D1B-F22C-4B9B-BE94-04675AF56957Q28476035-7C0E3FC9-5105-4A17-8410-AC45A9513AE0Q28478722-12791D4B-94CC-425F-8155-CF8792F53CC8Q28533830-AFEAB0A4-E692-4E91-A809-CBE6FA9E0AE0Q28534464-9137484B-9633-4468-93D3-F84001FE7A8FQ28536951-96B52DCF-4DA3-4823-9833-CCE54ACC8527Q28553571-24BDD2CF-9B75-402F-80EC-35246F5D2CFCQ28596842-9052E504-4355-4154-A877-A1CB4A814A12Q30662286-A4BE9314-5230-47CF-A39A-116412B20BECQ30815467-0DF0D97D-63E1-41AC-9A99-A65008878A25Q30911112-C93C8084-42C0-42DA-BA1D-F638337A9DDFQ33488152-495A1A69-68AC-48D5-B755-B42D3E8DF3FEQ33559145-1304724F-D126-4D09-B360-38EC7C518005Q33559216-5A95F400-9462-4490-BDD9-E5802B3E3338Q33570427-DBF2B853-9C1C-4A88-A84F-926861CA7CCBQ33629439-178C0EE1-4EDB-4510-9882-531300829EA4Q33725024-824F52A4-BB39-4DEF-ABB4-F5D1A3293782Q33758191-221397C1-9078-41AD-A7CC-E6A23DF0168CQ33786815-10CD27BC-1C2E-4A80-964D-AD248327EF02Q33838063-D33072C1-CCB5-42CB-B0B5-991AEB8E0C84Q33877347-E8107390-DF4A-40AA-8AE4-8543DDE97DC9Q33910771-9A158856-4B54-4D68-9135-4901F53818FDQ33931265-19AFF09F-C7BB-417A-ABA7-2FAD83E197E1Q33935930-CEC11782-8E55-447B-9223-8BDE47EE145FQ33963458-FA671F97-3A75-4FE1-9B61-A57CE8564B3EQ33973930-C5FAF220-D8E7-4A72-A5FE-072AE0D85E0DQ34005333-DC782E5B-3182-419B-A5F0-EF6FF874047CQ34050693-791ADEC3-B5DC-4095-8CDF-A45900FBED01Q34059575-E0FEB7D2-AB06-406C-A7E3-FDA93508CD91Q34059896-B073B35D-4769-4C52-8685-F348015ADC83Q34108775-E650C399-112F-43DA-A94D-0F078DD6FBFF
P2860
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
@en
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
@nl
type
label
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
@en
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
@nl
prefLabel
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
@en
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
@nl
P2093
P50
P356
P1476
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
@en
P2093
Anne R Meibohm
BENCHMRK Study Teams
Bach-Yen Nguyen
Daria J Hazuda
David A Cooper
Desmond M Ryan
Hedy Teppler
Jeffrey L Lennox
John A Killar
P304
P356
10.1056/NEJMOA0708978
P407
P577
2008-07-01T00:00:00Z